chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Case received from a healthcare professional through MIS on 23 September 2008 under the local reference number 08-0440. This case was reported as not-serious. However, upon internal review, it has been upgraded to serious (important medical condition). A 29-year-old female patient, with a medical history of allergies to PC (penicillin) and latex, had received her intramuscular dose of FLUZONE (batch number U2474AA) in the left deltoid, on 19 September 2008. Four hours post-vaccination, the patient's throat started feeling like congestion. As evening progressed, the patient's throat felt tight and under ribs felt constricted. Ten and a half hours post-vaccination, belly button felt knot like, the patient developed fever and lower back pain. Kidneys felt achy and the patient developed amber colored urine. The patient got sweaty and had to change. She went back to sleep after taking MOTRIN. The patient recovered on 20 September 2008.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 65-year-old female patient (not pregnant) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "osteoarthritis" (unspecified if ongoing); "fibromyalgia" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Erythromycin op, reaction(s): "known allergies: Erythromycin OP". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: The efficacy of a vaccine product varies from one patient to another and can be affected by different factors; however, a contributory role of the suspect vaccine BNT162B2  to the reported event drug ineffective and COVID-19 cannot be ruled out. The ongoing pandemic with high community virus transmission is assessed as a confounding factor.
Extreme fatigue, body ache, fever (101.1) night of the injection and all the next day. I also had a rash develop on the wrist of the arm where I was injected.
During the evening on the day of injection the patient developed a egg sized lump on the back of the right arm.  When the arm was reassessed in the morning the upper right arm was swollen rea and warm to the touch from the mid upper arm down to the mid forearm.
Child here for shots around 11:00 3-21-07; around 8 pm that night-temp 101.2 vomited x1 achy. 3-23-07 temp, 100.5 oral-By Friday 3-23-07 feeling fine no fevers, aches or complaints.
16 YEAR OLD WAS ACCIDENTLY VACCINATED; A spontaneous report was received from other healthcare professional (Pharmacist) concerning a 16-years-old patient, received who Moderna's COVID-19 vaccine (mRNA-1273) accidentally.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 18 Feb 2021, the patient received their dose of mRNA-1273 (Batch Number: Unknown), intramuscularly in the shoulder for prophylaxis of COVID-19 infection.  On 18 Feb 2021, 16 -years-old patient was accidentally vaccinated with the Moderna Covid-19 vaccine  No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not reported.  The outcome of the event 16 -years-old patient was accidentally vaccinated with the Moderna Covid-19 vaccine was considered recovered.; Reporter's Comments: This report refers to a case of a 16-year-old patient with Product administered to patient of inappropriate age for mRNA-1273, lot # unknown, with no associated adverse events.   Event considered resolved.
Arthritis and Morton's toe pain increased significantly after Pfizer vaccines - all 3 shots resulted in inflammation and severe pain and metatarsalgia.
I had Tinnitus previously but it initially became worse after dose 2 as detailed in VAERS report (1773157). After my 4th Moderna dose, I noticed a day or so later that my Tinnitus was worse than usual. I remember watching TV and the sounds becoming really annoying, louder than usual. After the second dose when it became worse I did go to see an ENT and they tested my hearing, which came back fine, but after this 4th dose I did not consult anybody but did mention it several times to my Therapist. The Tinnitus remains the same and has not gotten better.
I was diagnosed with fibromyalgia before the vaccine but I noticed the pain got worse about 3-4 months ago. I noticed it was much worse in my joints. It would hurt when I would roll my shoulder and I had pain in my hips. The pain still persists until this day. I was referred to a physical therapist but it hasn't helped much. I also had an infection in my arm that started the day after I got the vaccine and I was prescribed antibiotics for it.
This is a spontaneous report from a contactable pharmacist. A 34 years old female patient received first dose of PREVNAR 13 (lot number J90092, expiry date May2016) on 30Jan2015 around 10:27 A.M., at 0.5 ml single, intramuscular. There were no concomitant vaccines administered on same date or within 8 weeks. Concomitant medications included dicyclomine at 10 mg twice a day, mirtazapine, at 15 mg once a day (at bedtime), clonazepam at 0.5 mg twice a day, flunisolide nasal spray (two sprays twice a day) and sertraline tablet at 200 mg daily (2 tablets daily). The patient was asplenic (she had surgery to remove her spleen years ago) and she had ongoing chronic sinusitis and ongoing depression. On 30Jan2015 in the evening, the patient felt sick and went to the emergency room. Symptoms at that time included progressive fever, malaise, weakness, chills, and light headedness. White blood cell count on 30Jan2015 was 34900. The patient was admitted to the hospital on 30Jan2015 and started antibiotics until 03Feb2015. White blood cell count on 31Jan2015 was 12200. C-reactive protein was 3.33 on unknown date and sedimentation rate was 8 on unknown date. The patient was discharged on 03Feb2015. The event "white count was 34900" was resolving at the time of the report. Other events outcome was unknown at the time of the report.
Patient presented into our clinic, on 02-20-04, with sibling. Seven month old sibling received immunizations. Mom asked of safety because of older brother had chicken pox, diagnosed by their family physician. Upon further questioning and observation of patient, he had break-through pox since 02-18-04 and more had since erupted since the initial doctor visit.  Patient had approximately 80 pox on trunk and two on right femur.  Some were crusted but none appeared to be blistered.  Other than itching, patient had no other symptoms.  Mother stated that child returned to school on 02/24/04 per doctors release.  Child was previously immunized as stated above.
24JUL97 lt arm sore;25JUL95 fever over 102 lt arm swollen from shoulder to elbow, looked like real bad sun burn-could not heal;24JUL97 to ER given pain med to help stop inflammation & ease pain;could not lift head, h/a;dx some type of rxn;
This spontaneous report was received from a Nurse refers to a patient of unknown age. On an unknown date, the patient was vaccinated with VARIVAX (Merck) Lot # J006804 (Expiry: 30-MAY-2015) (0.5 ml once) subcutaneous was stored at 1C for 150 hours. No adverse effects reported. No further information provided. This case is linked to the case 1405USA000972 and 1405USA000973 (same reporter link). Additional information has been requested.
A report has been received from a Health Professional concerning a 54 year old, female subject, who had been receiving FLUMIST QUADRIVALENT. The patient's concurrent disease(s) included asthma. Concomitant medications included Paracetamol, Hormone Replacement Therapy and Cetirizine Hydrochloride for allergies. FLUMIST started on 07-Oct-2013. It was reported that consumer had administered vaccine during flu clinics and individual appointments but had not received FLUMIST but had been administering FLUMIST. The consumer experienced nasal congestion, congestion and headaches, sinus pain which started on 19-Oct-2013. At the time of reporting, the event of nasal congestion/congestion and headaches/sinus pain was ongoing and the outcome of the event of administered vaccine during flu clinics and individual appointments/have not received FLUMIST but have been administered FLUMIST is unknown. The report was considered to be non-serious.
extremely ill; sweating/body sweats; extreme abdominal pain; diarrhea; nausea; vomiting/vomiting bile; fatigued; Extreme headache; stomach cramping; copper taste left in my mouth like patients receiving chemo treatments; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): US-PFIZER INC-2021411940 (Pfizer).  A 51 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 08Apr2021 15:45 (Lot number: EW0158) at the age of 51 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Colitis" (unspecified if ongoing); "allergies" (unspecified if ongoing), notes: Eggs, cashews. The patient's concomitant medications were not reported. The following information was reported: ILLNESS (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "extremely ill"; HYPERHIDROSIS (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "sweating/body sweats"; ABDOMINAL PAIN (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "extreme abdominal pain"; DIARRHOEA (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "diarrhea"; NAUSEA (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "nausea"; VOMITING (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "vomiting/vomiting bile"; FATIGUE (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "fatigued"; HEADACHE (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "Extreme headache"; ABDOMINAL PAIN UPPER (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "stomach cramping"; TASTE DISORDER (non-serious) with onset 10Apr2021 21:45, outcome "recovering", described as "copper taste left in my mouth like patients receiving chemo treatments". Therapeutic measures were not taken as a result of illness, hyperhidrosis, abdominal pain, diarrhoea, nausea, vomiting, fatigue, headache, abdominal pain upper, taste disorder.  Additional information: Patient states that in 48 hours after her 1st vaccine, she became extremely ill. she was sweating and head felt like it was in a vice. Had extreme abdominal pain, diarrhoea, nausea, vomiting bile that left a copper taste in my mouth that continued for another 48 hours. she was extremely fatigued and felt the side effects she experienced are extremely similar to chemotherapy. She was questioning getting the second round based on her violent experience with the first.  Facility type for vaccine administration was other. Patient did not receive any other vaccine in four weeks. Patient did not receive any other medications in two weeks. Patient did not have covid prior vaccination. Patient was not covid tested post vaccination.   No follow-up attempts are possible. No further information is expected.
Administered past the 30 day refrigeration time; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered past the 30 day refrigeration time) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered past the 30 day refrigeration time). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered past the 30 day refrigeration time) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information reported.
This spontaneous report as received from a 67 years old female consumer refers to herself with no pertinent medical history. The patient was vaccinated with ZOSTAVAX (lot number, dose, route not reported) on 30-APR-2012. There were no concomitant medications. The patient experienced a severe red rash, swelling, warmth and pain at the injection site immediately after receiving the ZOSTAVAX vaccination on 30-APR-2012. She was seen by her primary doctor who advised her to expect this sort of reaction. No treatment was given. No laboratory diagnostics studies were performed. The symptoms lasted for about one week and then completely resolved approximately on 07-MAY-2012. Her husband who received the vaccination at the same time also had an adverse experience (captured in MARRS# 1211USA010774). Additional information is not expected.
got the shingles on right side of my face And, I got the shot/Suspected Vaccination failure; got the shingles on right side of my face; The pain has been non stop; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure, shingles and pain were unknown.  It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by the patient for herself or himself. The age at vaccination was not reported. The patient received the shingles vaccine. The patient stated that the approximately 3 and half years before the date of reporting and the patient experienced shingles on right side of his/her face. The patient also stated that the might be 6 months out of 3 and half years the patient had been pain free, but the pain has been non stop. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule and laboratory test confirming shingles were unknown at the time of reporting.
my arm is sore; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (my arm is sore) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On an unknown date, the patient experienced MYALGIA (my arm is sore). At the time of the report, MYALGIA (my arm is sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
PT c/o lymph nodes under on arm and neck swollen occurring 3-4 days post injection.
Fever  100-101. Extreme aching in body  Headache  AFTER 4 DAYS FELT OKAY !!!!!
This spontaneous report was received from a physician refers to a physician's daughter's friend of unknown age, who in an unknown date was vaccinated with a dose of GARDASIL (dose, route and lot number not reported). No other co-suspects were reported. No concomitant medications were reported. The physician reported that on an unknown date, the patient developed hair loss after receiving GARDASIL. At the time of the report, the patient's outcome was unknown. It was unspecified if the patient sought medical attention. This is one of several reports from the same source. Additional information has been requested.
pt given vax 12MAY93; 12 hrs later began feeling tingling & burning on lt side of scalp; had hypoesthesia on lt scalp over lt ear; MD told pt may take several months to resolve; ear ache; sudden lump on scalp which was tender; neuropathy;
After 12 hours, extreme shakes and shivers, hot and cold,  fainted and possible seizure for approximately 30-45 seconds- could not move or speak- was unresponsive  and panting- cognitively aware but unresponsive.
A nurse reported that a pt received an injection of Pnu-Imune 23. Within 3 days of vaccination, the pt developed an injection site reaction characterized by soreness and redness extending from elbow to shoulder. The pt was seen by the physician. The reporter indicated that 6 pts experienced this event; however, they are not presently identifiable. Additional reports will be generated when identifying information is provided.
Swelling and redness outer aspect of left arm. Noted by child's mother and grandmother. Child's temp checked-afebrile. Child refused Tylenol from mother. Cold wash cloth applied by grandmother.
Non toxic well appearing 6 yo female here for concerns over receiving concentrated COVID vaccine yesterday (adult dose rather than children's dose) and now with fever, chills, bodyaches, and pain at injection site. Note these side effects are common in patient for a few day after receiving COVID vaccine.
A patient was administered 1st dose that was drawn and kept in refrigerator beyond 12 hours; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 26-Jul-2021 and was forwarded to Moderna on 26-Jul-2021.    This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A patient was administered 1st dose that was drawn and kept in refrigerator beyond 12 hours) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (A patient was administered 1st dose that was drawn and kept in refrigerator beyond 12 hours). On 25-Jul-2021, EXPIRED PRODUCT ADMINISTERED (A patient was administered 1st dose that was drawn and kept in refrigerator beyond 12 hours) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided  Treatment information was not provided
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 10Oct2022 at 16:00 as dose 4 (booster), single (Lot number: GH9693) at the age of 46 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "High Blood Pressure" (unspecified if ongoing). Concomitant medication(s) included: LOSARTAN, start date: Jan2013; PRAVASTATIN, start date: Jan2013. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19. The patient received PAXLOVID as Covid-19 treatment. The patient has no known allergies.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect products to the reported events Drug ineffective and COVID-19 cannot be ruled out, based on the limited information currently available.
About a day or two after receiving my vaccine, I experienced all the normal side effects (fatigue, soreness, etc); About a day or two after receiving my vaccine, I experienced all the normal side effects (fatigue, soreness, etc); The side effect that cause concern for me was the swelling of my lymph nodes under my jawline.; They didnt hurt, but they were tender; Made my throat feel enflamed.; More discomfort than pain; It did affect my breathing; It did affect my breathing and ingestion of food to a degree.; This is a spontaneous report from a non-contactable consumer, the patient. A 27-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration on an unknown date in Apr2021 (at the age of 27-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, about a day or two after receiving his vaccine, the patient experienced all the normal side effects like fatigue, soreness, etc. The side effect that caused concern for the patient was the swelling of his lymph nodes under his jawline. They didn't hurt, but they were tender and made his throat feel enflamed. There was more discomfort than pain. The patient couldn't say any other symptoms arose, but it did affect his breathing and ingestion of food to a degree. It was two weeks post-first dose and the swelling was down a bit, but the lymph nodes still felt tender. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event swelling of lymph nodes under jawline was resolving, while that of they didn't hurt, but they were tender was not resolved. The clinical outcome of the events about a day or two after receiving vaccine, experienced all the normal side effects like fatigue, soreness, etc; throat felt enflamed; there was more discomfort than pain; it did affect breathing and ingestion of food to a degree was unknown at the time of this report.   No follow-up attempts are possible. No further information is expected.
Adverse event: Vaccine was administered 3 weeks after beyond use date and is less effective. Treatment: Pt returning to our office for additional vaccine based on Pfizer and State of MA recommendations.
Hives, Uticaria, swelling, appearing daily since vaccination on different body parts.
Developed shingles on back of head - right side - severe headache, earache, neck, blisters.
Headache, nausea, tiredness, followed by skin rash, swelling, and pain below injection site. It's now 10/22/2015 and all symptoms except tiredness still present.